Methods for measuring concentrations of biomolecules
AssigneeC2N Diagnostics
InventorsTim West, Andrew Corey Paoletti
Life of this patent
Estimating the term…
Abstract
The present invention provides methods for measuring the absolute concentration of a biomolecule of interest in a subject. Such biomolecules may be implicated in one or more neurological and neurodegenerative diseases or disorders. Also provided is a method for determining whether a therapeutic agent affects the in vivo metabolism of a central nervous system derived biomolecule. Also provided are kits for performing the methods of the invention.
Claims29
A method of calculating the concentration of a biomolecule in a subject comprising:
- (a) contacting a sample from the subject with a Quantitation Standard, wherein the Quantitation Standard comprises a known concentration of a labeled biomolecule of interest;
- (b) isolating the biomolecule of interest from the sample, wherein (a) and (b) can occur in reverse order;
- (c) determining a ratio of labeled to unlabeled biomolecules in the sample;
- and
- (d) calculating the concentration of the unlabeled biomolecule in the sample.
An in vivo method of quantifying the concentration of one or more biomolecules in a subject comprising:
- (a) administering one or more labeled amino acids to the subject, wherein the labeled amino acids incorporate into a biomolecule of interest in the subject;
- (b) obtaining a sample of biological fluid or tissue from the subject, wherein the sample comprises a labeled biomolecule fraction and an unlabeled biomolecule fraction;
- (c) contacting the sample with a Quantitation Standard, wherein the Quantitation Standard comprises a known concentration of a biomolecule labeled with a moiety that has a molecular weight that differs from the one or more labeled amino acids administered to the subject;
- (d) determining a ratio of labeled to unlabeled biomolecules in the sample, a ratio of labeled biomolecule to the Quantitation Standard, and a ratio of unlabeled biomolecule to the Quantitation Standard;
- and
- (e) calculating the concentration of the unlabeled biomolecule and the concentration of the labeled biomolecule in the sample.
A kit for diagnosing or monitoring the progression or treatment of a neurological or neurodegenerative disease in a subject, the kit comprising:
- (a) one or more labeled amino acids;
- (b) means for administering the one or more labeled amino acids to the subject, whereby the labeled amino acids are capable of incorporating into and labeling a biomolecule of interest in the subject;
- (c) means for obtaining a biological sample at regular time intervals from the subject, wherein the sample comprises a labeled biomolecule fraction and an unlabeled biomolecule fraction;
- (d) instructions for detecting and determining the ratio of labeled to unlabeled biomolecules of interest over time and for calculating the concentration of the unlabeled biomolecule in the sample, whereby the concentration of unlabeled biomolecule may be compared to the concentration of the same biomolecule in a corresponding normal sample, to the concentration of the same biomolecule in a subject of known neurological or neurodegenerative disease state, to the concentration of the same biomolecule from the same subject determined at an earlier time, or any combination thereof.
Dependencies are inferred from the claim text.